Health-related quality of life of postmenopausal women treated with Letrozole as adjuvant therapy for hormone receptor-positive early breast cancer (SBCCSG-15)
Not Applicable
- Conditions
- postmenopausal breast cancer
- Registration Number
- JPRN-UMIN000001552
- Lead Sponsor
- PO Saitama Breast Cancer Clinical Study Group (SBCCSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Female
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1. patients have been treated with medicine which may have some effect for sex hormone or trastuzumab 2. patients being treated with chemotherapy 3. Serious complications ( e.g malignant hypertension, CHF, hepatic failure, MI within 6 months, PE, arrhythmia treatment needed, infection, hemorrhagic tendency ) 4. active multiple cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change rate of FACT-ES score
- Secondary Outcome Measures
Name Time Method Change rate of FACT-G score Arthralgia related with AI FACT-ES score by baseline characters before and after treatment Difference of the evaluation of arthralgia between investigators and patients-self